Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: A synergistic combination nanotherapy for ovarian cancer treatment

Biomaterials

Volumn 37, Issue , 2015, Pages 456-468

  Cai, Liqiong ^a,b   Xu, Gaofei ^a,c   Shi, Changying ^a   Guo, Dandan ^a   Wang, Xu ^a   Luo, Juntao ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c CHINA AGRICULTURAL UNIVERSITY   (China)

Author keywords

Cisplatin; Combination chemotherapy; Drug delivery; Ovarian cancer; Paclitaxel; Synergism

Indexed keywords

CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; CYTOTOXICITY; DISEASES; DRUG DELIVERY; DRUG INTERACTIONS; ENZYME INHIBITION; TUMORS;

CIS-PLATIN; COMBINATION CHEMOTHERAPY; OVARIAN CANCERS; PACLITAXEL; SYNERGISM;

TARGETED DRUG DELIVERY;

CARBOXYLIC ACID; CHOLIC ACID DERIVATIVE; CISPLATIN; DENDRIMER; NANOCARRIER; PACLITAXEL; TELODENDRIMER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CLICK CHEMISTRY; COMPLEX FORMATION; CONTROLLED STUDY; CRITICAL MICELLE CONCENTRATION; CYTOTOXICITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RELEASE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LOW DRUG DOSE; MICELLE; MOUSE; NANOENCAPSULATION; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TUMOR XENOGRAFT; VOLUME OF DISTRIBUTION; ANIMAL; BODY WEIGHT; CELL DEATH; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; FLUORESCENCE MICROSCOPY; IC50; LIGHT; MASS SPECTROMETRY; NUDE MOUSE; PARTICLE SIZE; PROTON NUCLEAR MAGNETIC RESONANCE; RADIATION SCATTERING; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CELL DEATH; CELL SURVIVAL; CISPLATIN; DENDRIMERS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; LIGHT; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; PROTON MAGNETIC RESONANCE SPECTROSCOPY; SCATTERING, RADIATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TISSUE DISTRIBUTION; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922250825     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.10.044     Document Type: Article

References (38)

1. Rowinsky E.K., Gilbert M.R., McGuire W.P., Noe D.A., Grochow L.B., Forastiere A.A., et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. JClin Oncol 1991, 9:1692-1703.
2. Rowinsky E.K., Citardi M.J., Noe D.A., Donehower R.C. Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. JCancer Res Clin Oncol 1993, 119:727-733.
3. Milross C.G., Peters L.J., Hunter N.R., Mason K.A., Milas L. Sequence-dependent antitumor activity of paclitaxel (taxol) and cisplatin invivo. Int J Cancer 1995, 62:599-604.
4. Sacchi A., Gasparri A., Gallo-Stampino C., Toma S., Curnis F., Corti A. Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha. Clin Cancer Res 2006, 12:175-182.
5. Coleman R.L., Monk B.J., Sood A.K., Herzog T.J. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 2013, 10:211-224.
6. Banerjee S., Kaye S.B. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res 2013, 19:961-968.
7. Undevia S.D., Gomez-Abuin G., Ratain M.J. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 2005, 5:447-458.
8. Atta H., Beijnen J.H., Vermorken J.B., Schellens J.H.M. Pharmacokinetics and pharmacodynamics of anticancer agents used in gynaecological oncology. CME J Gynecol Oncol 2001, 5-16.
9. Spratlin J., Sawyer M.B. Pharmacogenetics of paclitaxel metabolism. Crit Rev Oncol Hematol 2007, 61:222-229.
10. Sonnichsen D.S., Liu Q., Schuetz E.G., Schuetz J.D., Pappo A., Relling M.V. Variability in human cytochrome P450 paclitaxel metabolism. JPharmacol Exp Ther 1995, 275:566-575.
11. Wensing K.U., Ciarimboli G. Saving ears and kidneys from cisplatin. Anticancer Res 2013, 33:4183-4188.
12. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzym Regul 2001, 41:189-207.
13. Noguchi Y., Wu J., Duncan R., Strohalm J., Ulbrich K., Akaike T., et al. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 1998, 89:307-314.
14. Oberoi H.S., Nukolova N.V., Kabanov A.V., Bronich T.K. Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev 2013, 65:1667-1685.
15. Desale S.S., Cohen S.M., Zhao Y., Kabanov A.V., Bronich T.K. Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer. JControl Release 2013, 171:339-348.
16. Song W., Tang Z., Zhang D., Zhang Y., Yu H., Li M., et al. Anti-tumor efficacy of c(RGDfK)-decorated polypeptide-based micelles co-loaded with docetaxel and cisplatin. Biomaterials 2014, 35:3005-3014.
17. Xiao H., Song H., Zhang Y., Qi R., Wang R., Xie Z., et al. The use of polymeric platinum(IV) prodrugs to deliver multinuclear platinum(II) drugs with reduced systemic toxicity and enhanced antitumor efficacy. Biomaterials 2012, 33:8657-8669.
18. Kolishetti N., Dhar S., Valencia P.M., Lin L.Q., Karnik R., Lippard S.J., et al. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci U S A 2010, 107:17939-17944.
19. Xiao H., Li W., Qi R., Yan L., Wang R., Liu S., et al. Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer and more efficacious combination therapy. JControl Release 2012, 163:304-314.
20. Xiao H., Song H., Yang Q., Cai H., Qi R., Yan L., et al. Aprodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance. Biomaterials 2012, 33:6507-6519.
21. Wang L.H., Li Y., Yang S.N., Wang F.Y., Hou Y., Cui W., et al. Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-kappaB and MAPK/HO-1 signalling. Br J Cancer 2014, 110:341-352.
22. Luo J., Xiao K., Li Y., Lee J.S., Shi L., Tan Y.H., et al. Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment. Bioconjug Chem 2010, 21:1216-1224.
23. Xiao K., Luo J., Fowler W.L., Li Y., Lee J.S., Xing L., et al. Aself-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials 2009, 30:6006-6016.
24. Song A., Wang X., Zhang J., Marik J., Lebrilla C.B., Lam K.S. Synthesis of hydrophilic and flexible linkers for peptide derivatization in solid phase. Bioorg Med Chem Lett 2004, 14:161-165.
25. Hoyle C.E., Bowman C.N. Thiol-ene click chemistry. Angew Chem Int Ed 2010, 49:1540-1573.
26. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006, 58:621-681.
27. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul 1984, 22:27-55.
28. King F.G., Dedrick R.L. Physiological pharmacokinetic parameters for cis-dichlorodiammineplatinum(II) (DDP) in the mouse. JPharmacokinet Biopharm 1992, 20:95-99.
29. Kaiser E., Colescott R.L., Bossinger C.D., Cook P.I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem 1970, 34:595-598.
30. Huynh V.T., Chen G., de Souza P., Stenzel M.H. Thiol-yne and thiol-ene "click" chemistry as a tool for a variety of platinum drug delivery carriers, from statistical copolymers to crosslinked micelles. Biomacromolecules 2011, 12:1738-1751.
31. Bastiat G., Pritz C.O., Roider C., Fouchet F., Lignieres E., Jesacher A., et al. Anew tool to ensure the fluorescent dye labeling stability of nanocarriers: a real challenge for fluorescence imaging. JControl Release 2013, 170:334-342.
32. Jekunen A.P., Christen R.D., Shalinsky D.R., Howell S.B. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells invitro. Br J Cancer 1994, 69:299-306.
33. Horvath V., Blanarova O., Svihalkova-Sindlerova L., Soucek K., Hofmanova J., Sova P., et al. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells. Gynecol Oncol 2006, 102:32-40.
34. Eckstein N., Servan K., Hildebrandt B., Politz A., von Jonquieres G., Wolf-Kummeth S., et al. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res 2009, 69:2996-3003.
35. Zhang Y., Huo M., Zhou J., Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 2010, 99:306-314.
36. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008, 5:505-515.
37. Gabizon A.A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001, 19:424-436.
38. Vail D.M., Kravis L.D., Cooley A.J., Chun R., MacEwen E.G. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors. Cancer Chemother Pharmacol 1997, 39:410-416.